ストックスクリーナーアプリを入手
7.03
1.01%
0.07
前日終値:
$6.96
開ける：
$7.03
24時間の取引高:
1,620
Relative Volume:
0.27
時価総額：
$28.05M
収益：
-
当期純損益:
$-24.77M
株価収益率:
-9.6301
EPS:
-0.73
ネットキャッシュフロー:
$-17.36M
1週間 パフォーマンス:
-0.99%
1か月 パフォーマンス:
-10.56%
6か月 パフォーマンス:
-4.03%
1年 パフォーマンス:
-26.77%
1日の値動き範囲:
$6.98
$7.03
1週間の範囲:
$6.89
$7.395
52週間の値動き範囲:
$4.5601
$13.79
Mink Therapeutics Inc Stock (INKT) Company Profile
INKT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
7.03 | 28.30M | 0 | -24.77M | -17.36M | -0.73 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Mink Therapeutics Inc (INKT) 最新ニュース
(INKT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
MiNK Therapeutics outlines near-term partnering proposals and reduced cash burn as company advances iNKT programs - MSN
HC Wainwright Cuts Earnings Estimates for MiNK Therapeutics - Defense World
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2025 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Mink Therapeutics’ Earnings Call Highlights Progress and Optimism - TipRanks
Transcript : MiNK Therapeutics, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
MiNK Therapeutics (INKT) Advances in Immune Response Innovation - GuruFocus
MiNK Therapeutics (INKT) Advances in Immune Response Innovation | INKT Stock News - GuruFocus
MiNK Therapeutics Reports Clinical Advancements and Financial Update for Q1 2025, with Focus on iNKT Cell Therapies - Nasdaq
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress - GlobeNewswire
MiNK Therapeutics (INKT) Projected to Post Earnings on Tuesday - Defense World
Refractory Multiple Myeloma Pipeline Appears Robust With 75+ - openPR.com
How to Take Advantage of moves in (INKT) - news.stocktradersdaily.com
MiNK Therapeutics to Announce Q1 2025 Financial Results and Host Conference Call on May 15th - Nasdaq
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report - GlobeNewswire
Geode Capital Management LLC Lowers Stock Position in MiNK Therapeutics, Inc. (NASDAQ:INKT) - Defense World
Learn to Evaluate (INKT) using the Charts - news.stocktradersdaily.com
Comparing Atyr PHARMA (NASDAQ:ATYR) and MiNK Therapeutics (NASDAQ:INKT) - Defense World
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia - Business Wire
LIfT BioSciences appoints new CSO - Bdaily
LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer - EIN News
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch - Business Wire
(INKT) Trading Report - news.stocktradersdaily.com
Reviewing MiNK Therapeutics (NASDAQ:INKT) & Creative Medical Technology (NASDAQ:CELZ) - The AM Reporter
Where are the Opportunities in (INKT) - news.stocktradersdaily.com
HC Wainwright Issues Negative Forecast for INKT Earnings - Defense World
What is William Blair’s Forecast for INKT Q1 Earnings? - Defense World
What is William Blair’s Estimate for INKT Q1 Earnings? - Defense World
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2024 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics (NASDAQ:INKT) Given Buy Rating at HC Wainwright - Defense World
MiNK Therapeutics Inc (INKT) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
MiNK Therapeutics Reports 2024 Progress and Financials - TipRanks
MiNK Therapeutics’ Earnings Call Highlights Strategic Gains - TipRanks
MiNK Therapeutics, Inc. SEC 10-K Report - TradingView
Earnings call transcript: Mink Therapeutics Q4 2024 reports reduced net loss - Investing.com
Mink Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress - GlobeNewswire
MiNK Therapeutics Reports 2024 Financial Results and Highlights Clinical Advancements in iNKT Cell Therapies - Nasdaq
MiNK Therapeutics reports Q4 EPS (62c), consensus (50c) - TipRanks
Earnings Scheduled For March 18, 2025 - Benzinga
AGENUS INC SEC 10-K Report - TradingView
(INKT) Technical Pivots with Risk Controls - Stock Traders Daily
Mink Therapeutics Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView
New Strong Buy Stocks for July 11th - MSN
The Future of Refractory Multiple Myeloma Therapy: 75+ - openPR
MiNK Therapeutics, Inc. to Announce Fourth Quarter and Year End 2024 Financial Results on March 18th - Nasdaq
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report - GlobeNewswire
When Will MiNK Therapeutics Reveal Its 2024 Financial Performance? - StockTitan
What is HC Wainwright’s Estimate for INKT Q1 Earnings? - Defense World
Mink Therapeutics Inc (INKT) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):